Comparison

Atazanavir (sulfate) European Partner

Item no. HY-17367A-100mg
Manufacturer MedChem Express
CASRN 229975-97-7
Amount 100 mg
Quantity options 100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category
Type Inhibitors
Specific against other
Purity 99.87
Citations [1]Havlir DV, et al. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004 Jun 1;38(11):1599-604.|[2]Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96.|[3]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.|[4]Zhang G, et al. Long-term oral atazanavir attenuates myocardial infarction-induced cardiac fibrosis. Eur J Pharmacol. 2018 Jun 5;828:97-102.|[5]Fukushima K, et al. Effect of serum lipids on the pharmacokinetics of atazanavir in hyperlipidemic rats. Biomed Pharmacother. 2009 Nov;63(9):635-42. |[6]Pyrko P, et al. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res. 2007 Nov 15;67(22):10920-8. |[7]Alomar FA, et al. Efavirenz, atazanavir, and ritonavir disrupt sarcoplasmic reticulum Ca2+ homeostasis in skeletal muscles. Antiviral Res. 2021 Mar;187:104975. |[8]Robillard KR, et al. Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract. Antimicrob Agents Chemother. 2014;58(3):1713-22.
bioRxiv. 2020 Apr.|Curr Protoc. 2021 Feb;1(2):e32.|Nat Commun. 2020 Apr 14;11(1):1792.|Nat Commun. 2020 Sep 4;11(1):4417.|Signal Transduct Target Ther. 2021 May 29;6(1):212.|Aging Cell. 2022 Dec 20;e13750.|Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00872-20.|Faculty of Pharmacy in Hradec Králové Department of Pharmacological and Toxicology. University of Oxford. 2019 Jul.|Int J Antimicrob Agents. 2019 Dec;54(6):814-819.|PLoS Biol. 2020 Jan 16;18(1):e3000599. |Research Square Print. 2022 May.
Smiles O=C(OC)N[C@@H](C(C)(C)C)C(NN(CC1=CC=C(C2=NC=CC=C2)C=C1)C[C@H](O)[C@H](CC3=CC=CC=C3)NC([C@H](C(C)(C)C)NC(OC)=O)=O)=O.O=S(O)(O)=O
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias BMS-232632 sulfate
Shipping Condition Room temperature
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
COVID-19-anti-virus
Manufacturer - Targets
Cytochrome P450; Endogenous Metabolite; HIV; HIV Protease; P-glycoprotein; SARS-CoV; Toll-like Receptor (TLR)
Shipping Temperature
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Molecular Weight
802.93
Product Description
Atazanavir (BMS-232632) sulfate is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir sulfate is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. Atazanavir sulfate inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death[1][2][3][4][5][6][7][8].
Manufacturer - Research Area
Cancer; Infection; Cardiovascular Disease
Solubility
DMSO: 166 mg/mL (ultrasonic; warming)|H2O: < 0.1 mg/mL
Manufacturer - Pathway
Anti-infection; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease
Isoform
CYP3; HIV-1
Clinical information
Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close